Evoke Pharma Inc has entered into a merger agreement with QOL Medical to acquire all outstanding shares at $11.00 per share, effective November 3, 2025. The company's board unanimously supports the deal, which will transition Evoke to a wholly owned subsidiary of QOL Medical, ceasing its status as a publicly traded company.